“Praluent” (alirocumab), the first injectable drug that lowers the cholesterol levels was approved by the The U.S. Food and Drug Administration. I could change cardiovascular care, by cutting levels of LDL (the “bad cholesterol), as experts explained. For now, the drug is only approved for severely diseases patients, that suffered a strokeand need additional treatment, besides a healthy diet and lifestyle. Patients with heterozygous familial hypercholesterolemia (HeFH), an inherited illness that causes people to have high levels of cholesterol are also allowed to use Praluent.
“Praluent provides another treatment option for patients with HeFH or with known cardiovascular disease who have not been able to lower their LDL cholesterol enough on statins,” Dr. John Jenkins, director of the FDA’s Office of New Drugs, Center for Drug Evaluation and Research, said in the news release.
With Praluent, studies once again to back up the effectiveness of PCSK9 inhibitors in lowering LDL cholesterol that clogs arteries, also lowering by half the risk of a heart attack or death due to stroke, as researchers claim.
Praluent’s side-effects include “itching, swelling, pain, or bruising where injection is given, [colds] and flu” as well as allergic reactions at the injection site, FDA experts declared. Nevertheless, and despite the fact that Praluent is not at all cheap, the new drug seems to be more efficient and provokes less complications than Statin, previously used to lower LDL.
Despite good results, the trial still needs further assessments though, as it has only been conducted for a short period of time and only early data are available. The clinical trial will complete in 2017.